Improving Success with Pharmacologic Management of Symptomatic VMA

The use of stringent patient selection criteria can help increase resolution rates.

BY ARSHAD M. KHANANI, MD

In pivotal phase 3 trials, resolution of vitreomacular adhesion (VMA) was achieved in about one-quarter of patients 28 days after a single 125-μg intravitreal injection of ocriplasmin (Jetrea, ThromboGenics). Anatomic outcomes can be improved in clinical practice by applying predictive features when selecting patients most likely to benefit from this treatment.

BACKGROUND

Symptomatic VMA is a progressive, sight-threatening disorder that can lead to irreversible retinal damage and vision loss.1 Treatment options include watchful waiting, vitrectomy, or pharmacologic vitreolysis with ocriplasmin.1 Ocriplasmin is a recombinant truncated human plasmin that degrades extracellular proteins to induce vitreous liquefaction and vitreoretinal separation.2,3 The efficacy and safety of a single 125-μg intravitreal injection of ocriplasmin for treatment of symptomatic VMA was demonstrated in pivotal phase 3 randomized, placebo-controlled trials referred to collectively as MIVI-TRUST.4 The percentage of patients with pharmacologic VMA resolution 28 days after injection was significantly greater in the ocriplasmin group (26.5%) than the placebo group (10.1%; P < .001).4

A post hoc analysis of MIVI-TRUST findings identified 5 baseline features that are predictive of VMA resolution 28 days after ocriplasmin injection: age younger than 65 years, phakic lens status, VMA diameter less than or equal to 1500 μm, presence of a full-thickness macular hole (FTMH), and absence of an epiretinal membrane (ERM).5

To determine how these previously identified predictive factors may influence symptomatic VMA resolution rates in a clinical setting, we performed a retrospective analysis of medical records of patients who were treated with a single 125-μg intravitreal injection of ocriplasmin and were monitored with spectral-domain optical coherence tomography (SD-OCT) at our center between February 19, 2013, and November 26, 2013. Results from this retrospective case series analysis demonstrated that stringent patient selection doubled the likelihood of achieving positive outcomes in patients with symptomatic VMA treated with ocriplasmin (unpublished data).

RESULTS FROM CASE SERIES ANALYSIS

Medical records of patients with symptomatic VMA who were treated with a single 125-μg intravitreal injection of ocriplasmin and monitored with SD-OCT were selected for retrospective analysis. Patient consent and institutional review board exemption (New England Institutional Review Board) were obtained. Efficacy parameters analyzed included VMA resolution, FTMH closure, and BCVA change from baseline to final follow-up. Visual acuity was measured in Snellen lines and converted to logMAR for analysis. Safety parameters included ellipsoid zone alterations and subretinal fluid accumulation.

In total, 14 eyes of 12 patients were analyzed. Patient demographics and baseline ocular characteristics are reported in the Table. Of the overall population, half of all eyes (n = 7) achieved VMA resolution, with 5 cases resolving within 7 days of injection. Among eyes with FTMH at baseline (n = 5), 80% (n = 4) achieved hole closure. Visual acuity gain of more than 2 lines of BCVA was achieved in 29% (n = 4) of all eyes (Figure 1). Mean
BCVA changed from 20/67 (0.525 logMAR) at baseline to 20/48 (0.379 logMAR) at final follow-up (Table).

Resolution rates were then calculated for subgroups defined by the presence of each predictor of response identified in the previous post hoc analysis. All eyes of patients who were younger than 65 years (n = 5 of 5) achieved VMA resolution, as did all eyes with baseline FTMH (n = 5 of 5). Resolution was achieved in half (n = 7 of 14) of eyes with focal VMA (< 1500 μm) and half of those with no ERM at baseline (n = 6 of 12). Two-thirds of phakic eyes (n = 6 of 9) achieved resolution (Figure 2).

To evaluate the effect of more stringent patient selection criteria on symptomatic VMA resolution rates, eyes were divided into 2 groups based on injection date. Group 1 eyes were injected between February and May 2013 and selected according to "less stringent" criteria. Group 2 eyes were injected between July and November 2013 and were selected according to "more stringent" criteria based on predictors of response (eg, no ERM, FTMH present, and focal adhesion). Retrospective analysis revealed that group 1 eyes were older, were less likely to be phakic or have FTMH, and had larger adhesions (Table). All eyes with ERM (n = 2 of 10) were in group 1. Mean baseline BCVA was 20/75 (0.575 logMAR) in Group 1 and 20/62 (0.488 logMAR) in group 2. Mean follow-up time in both groups was 13 weeks. Interestingly, the percentage of patients achieving VMA resolution at final follow-up was nearly doubled in group 2 (63%; n = 5 of 8; Figure 3) compared with group 1 (33%; n = 2 of 6). At final follow-up, mean BCVA was 20/45 (0.350 logMAR) in group 1 and 20/50 (0.400 logMAR) in group 2.

No serious, irreversible adverse events were reported. Most patients reported photopsias and/or floaters, which usually resolved within 1 week. Four of 9 eyes had a normal ellipsoid zone at baseline that was altered after injection. More than half of eyes (n = 8) had subretinal fluid after injection. All cases of ellipsoid zone changes and subretinal fluid accumulation fully resolved by final follow-up.

### OCRIPLASMIN PATIENT SELECTION UTILIZING AN OCT-BASED CLASSIFICATION SYSTEM

The baseline features that have been identified as positively associated with higher rates of symptomatic VMA

---

**TABLE. BASELINE DEMOGRAPHICS AND OCULAR CHARACTERISTICS**

<table>
<thead>
<tr>
<th>Baseline Characteristics</th>
<th>Total</th>
<th>Group 1&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Group 2&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonocular</td>
<td>n = 12</td>
<td>n = 5</td>
<td>n = 7</td>
</tr>
<tr>
<td>Age, mean years (range)</td>
<td>69 (54-83)</td>
<td>78 (73-83)</td>
<td>63 (54-76)</td>
</tr>
<tr>
<td>Ocular</td>
<td>n = 14</td>
<td>n = 6</td>
<td>n = 8</td>
</tr>
<tr>
<td>FTMH present, n (%)</td>
<td>5 (36)</td>
<td>1 (17)</td>
<td>4 (50)</td>
</tr>
<tr>
<td>VMA diameter, mean µm (range)</td>
<td>436 (131-1119)</td>
<td>556 (232-1119)</td>
<td>346 (131-476)</td>
</tr>
<tr>
<td>ERM absent (%)</td>
<td>12 (86)</td>
<td>4 (67)</td>
<td>8 (100)</td>
</tr>
<tr>
<td>Phakic lens (%)</td>
<td>9 (64)</td>
<td>2 (33)</td>
<td>7 (88)</td>
</tr>
<tr>
<td>Mean BCVA, baseline, Snellen</td>
<td>20/67</td>
<td>20/75</td>
<td>20/62</td>
</tr>
<tr>
<td>Mean BCVA, final follow-up, Snellen</td>
<td>20/48</td>
<td>20/45</td>
<td>20/50</td>
</tr>
</tbody>
</table>

Abbreviations: BCVA, best corrected visual acuity; ERM, epiretinal membrane; FTMH, full-thickness macular hole; VMA, vitreomacular adhesion.<br><br><sup>a</sup> Group 1 eyes were injected between February and May 2013 and were selected with “less stringent” criteria.<br><br><sup>b</sup> Group 2 eyes were injected between July and November 2013 and were selected with “more stringent” criteria according to identified baseline predictors of response.
resolution, and shown in this case series to influence patient outcomes in a clinical setting, are best observed using OCT imaging (Figure 4). In 2013, a panel of international vitreoretinal experts created an anatomy-based scheme to support consistent definition and classification of VMA-associated pathologies. The IVTS group designed a classification system based on OCT anatomic criteria. It excluded clinical features, such as fundus findings or symptoms, because they can be subjective in nature.

According to the IVTS, both VMA and vitreomacular traction (VMT) can be classified as focal (< 1500 μm) or broad (> 1500 μm) depending on the diameter of persistent vitreomacular attachment. FTMH is defined as a foveal lesion that interrupts all layers of the retina from the internal limiting membrane through the retinal pigment epithelium. FTMH is also classified by the size of the hole (small ≤ 250 μm, medium > 250 to ≤ 400 μm, and large > 400 μm), and the presence or absence of persistent vitreous attachment. A standardized classification system such as this allows the consistent identification of appropriate candidates for ocriplasmin treatment and a better understanding of treatment outcomes.

Additional considerations are needed for those patients with symptomatic VMA/VMT associated with a FTMH. The size of the FTMH is an important determinant when selecting patients for ocriplasmin treatment. Data from the pivotal phase 3 trials showed that the success rate was directly proportional to the size of the FTMH; 58% of eyes with a FTMH less than or equal to 250 μm and 37% of eyes with a FTMH between 250 and 400 μm achieved nonsurgical closure. Although investigators intended to exclude eyes with FTMH larger than 400 μm from the trials, 19 patients with a FTMH larger than 400 μm were treated with ocriplasmin; none of these eyes achieved resolution. It is also important to note that ocriplasmin is not indicated to treat FTMH in the absence of any VMA/VMT, and that vitrectomy is the best option for these patients.

**CONCLUSION**

The critical role of patient selection in optimizing ocriplasmin treatment outcomes is underscored by the identification of baseline predictors of anatomic success. In this retrospective analysis, the clinical population was divided into 2 groups based on the date of injection, which is a surrogate for the application of “less stringent” or “more stringent” patient selection according to baseline predictors. Rates of VMA resolution after injection were higher among patients who were more stringently selected compared with those who were less stringently selected. Our results from a small case series support the use of predictive features in order to select patients who are most likely to benefit from ocriplasmin injection, and these findings are corroborated by other clinical case series reports.

**Arshad Khanani, MD**, is a clinical assistant professor at the University of Nevada School of Medicine and managing partner at Sierra Eye Associates in Reno, Nevada. He is a consultant and speaker for ThromboGenics. Dr. Khanani may be reached at arshad.khanani@gmail.com.

Meridia Health Communications, Inc. provided support in manuscript writing and preparation.

Dr. Khanani had full access to all of the case data and takes full responsibility for the integrity of the data and reported findings.

---